

# Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial

Susan J. Diem, MD, MPH,<sup>1,2</sup> Katherine A. Guthrie, PhD,<sup>3</sup> Caroline M. Mitchell, MD, MPH,<sup>4</sup>  
Susan D. Reed, MD, MPH,<sup>5</sup> Joseph C. Larson, MS,<sup>3</sup> Kristine E. Ensrud, MD, MPH,<sup>1,2</sup>  
and Andrea Z. LaCroix, PhD<sup>6</sup>

---

## Abstract

**Objective:** Compare the effects of a vaginal estradiol tablet and a vaginal moisturizer, each to placebo, on menopause-related quality of life and mood in postmenopausal women with moderate–severe vulvovaginal symptoms.

**Methods:** A total of 302 postmenopausal women enrolled in a 12-week, double-blind, placebo-controlled randomized trial were assigned to vaginal 10 µg estradiol tablet plus placebo gel ( $n = 102$ ), vaginal moisturizer plus placebo tablet ( $n = 100$ ), or dual placebo ( $n = 100$ ). We measured change from randomization to 12 weeks in total score of the Menopause-Specific Quality of Life (MENQOL) questionnaire. We also evaluated the four MENQOL domains, depressive symptoms as measured by the Patient Health Questionnaire 8, and anxiety symptoms as measured by the Generalized Anxiety Disorder (GAD-7) questionnaire.

**Results:** Treatment with vaginal estradiol resulted in significantly greater improvement in total MENQOL scores compared to dual placebo (mean difference between arms  $-0.3$  at 12 weeks (95% confidence interval [CI]  $-0.5, 0.0$ ;  $P = 0.01$ ). A statistically significant group mean difference favoring vaginal estradiol was observed for the MENQOL sexual function domain ( $-0.4$  at 12 weeks; 95% CI  $-1.0, 0.1$ ;  $P = 0.005$ ), but not for any of the other domains. Treatment with vaginal moisturizer did not provide greater improvement compared to placebo in total MENQOL scores (mean difference  $0.2$  at 12 weeks; 95% CI  $-0.1, 0.4$ ;  $P = 0.38$ ) or in any of the MENQOL domains. Neither treatment group showed improvement compared with placebo in the Patient Health Questionnaire 8 or Generalized Anxiety Disorder Questionnaire.

**Conclusions:** Treatment with low-dose vaginal estradiol, but not vaginal moisturizer, modestly improved menopause-related quality of life and sexual function domain scores in postmenopausal women with moderate–severe vulvovaginal symptoms.

**Key Words:** Anxiety – Clinical trials network – Depressive symptoms – Postmenopausal vulvovaginal symptoms – Quality of life – Vaginal estrogen – Vaginal moisturizer.

---

Bothersome vulvovaginal symptoms including lack of lubrication and discomfort or pain with vaginal intercourse are prevalent amongst postmenopausal women,<sup>1-3</sup> with up to 75% reporting vaginal dryness and up to 40% reporting pain with intercourse.<sup>2,4</sup> Moderate to severe vulvovaginal symptoms in postmenopausal women are associated with significant decreases in sexual functioning<sup>5,6</sup> and in quality of life (QOL), comparable to the effects of other

chronic conditions such as arthritis, asthma, and irritable bowel syndrome.<sup>1</sup>

Current treatment options for postmenopausal vulvovaginal symptoms include vaginal treatments<sup>7,8</sup> such as vaginal estrogen creams, tablets, or rings; vaginal moisturizers; intra-vaginal prasterone (dehydroepiandrosterone)<sup>9</sup>; as well as the oral selective estrogen receptor modulator ospemifene.<sup>10</sup> Randomized, double-blind, placebo-controlled clinical trials

---

Received February 26, 2018; revised and accepted April 3, 2018.

From the <sup>1</sup>Department of Medicine and Epidemiology and Community Health, University of Minnesota, Minneapolis, MN; <sup>2</sup>Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN; <sup>3</sup>Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>4</sup>Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; <sup>5</sup>Department of Obstetrics and Gynecology, University of Washington, Seattle, WA; and <sup>6</sup>Department of Family Medicine and Public Health, University of California at San Diego, La Jolla, CA.

Funding/Support: This study was funded by the National Institutes of Health/National Institute on Aging: R01 AG048209. The sponsor had no input in or control over the analysis of data, writing of manuscript, or decision to publish. All of the opinions and conclusions reported herein are the authors' own, and do not reflect the official position of the National Institute of Aging.

Clinical trial registration: Clinical trials.gov: NCT02516202.

Address correspondence to: Susan J. Diem, MD, MPH, One Veterans Dr, General Internal Medicine (111-0), Minneapolis, MN 55417.  
E-mail: sdiem@umn.edu

have demonstrated that vaginal estrogen creams,<sup>11,12</sup> vaginal estrogen tablets,<sup>13-16</sup> intravaginal prasterone (dehydroepiandrosterone),<sup>9</sup> and ospemifene<sup>10,17</sup> reduce vulvovaginal symptoms, although few of these trials have examined the effects of treatment on QOL or mood. Limited data exist to support the use of vaginal moisturizers and no studies have examined their effects on QOL.<sup>18-20</sup>

The Menopause Strategies: Finding Lasting Answers for Symptoms and Health clinical trials network recently completed a three-arm double blind trial of vaginal estradiol tablets, a vaginal moisturizer, and matching placebos for each to examine the efficacy of vaginal estradiol and vaginal moisturizer relative to placebo in improving genitourinary symptoms of menopause. The primary results of that trial showed no benefit over placebo for the vaginal estradiol tablet or moisturizer in reducing severity of most bothersome symptom.<sup>21</sup> Herein we report the effects of vaginal estradiol tablet plus placebo gel or vaginal moisturizer plus placebo tablet versus dual placebo on menopause-related QOL, depressive symptoms, and anxiety.

## METHODS

### Study design

A randomized, double-blind, placebo-controlled 12-week trial was conducted among women with moderate-severe vulvovaginal symptoms recruited at two sites: Kaiser Permanente Washington Health Research Institute in Seattle, WA and University of Minnesota in Minneapolis, MN. The protocol was approved by the institutional review board at each site and at the Data Coordinating Center. All women provided written informed consent.

The trial enrolled 302 women from April 2016 to February 2017. Women were eligible if they were 45 to 70 years old, 2 or more years since last menses, reported 1 or more moderate-severe symptom of vulvovaginal itching, pain, dryness, or irritation experienced at least weekly within the past 30 days; or pain with penetration at least once monthly. Exclusion criteria included current vaginal infection; use of hormonal medication in past 2 months; use of antibiotics, vaginal moisturizer, probiotic, prebiotic, or douche in past month; and chronic premenopausal vulvovaginal symptoms. Additional details of the trial design and methods were published previously.<sup>21</sup>

### Treatment and study procedures

Women were recruited through direct mailings and Facebook ads targeted to women aged 50 to 70 years within 20 miles of the clinical sites. Randomization by permuted blocks of 9 and stratified by site was conducted in a secure Web-based database, and implemented via a computerized inventory system for dispensing identical-appearing tablets in bottles and gel in tubes. Participants, study personnel, and clinical providers were blinded to treatment assignments.

Women were randomly assigned 1:1:1 to vaginal estradiol 10 mcg tablet (Vagifem) + placebo vaginal gel (hydroxyethyl

cellulose); placebo vaginal tablet + vaginal moisturizer (Replens); or placebo tablet + placebo gel. The composition of the placebo vaginal gel, vaginal moisturizer, and placebo tablet have been described previously.<sup>21</sup>

Women were instructed to use the vaginal tablet (active or placebo) daily for 2 weeks, then twice weekly for the remaining 10 weeks. The vaginal gel (active or placebo) was to be used every 3 days throughout the trial. During the first 2 weeks, participants were advised to use tablet in the morning and gel in the evening. After that participants were instructed to use the products on alternate days.

### Data collection

Telephone contact at 1, 3, and 11 weeks postrandomization assessed protocol adherence and adverse events. Follow-up clinic visits were conducted 4 and 12 weeks postrandomization and included completion of questionnaires regarding menopause-specific QOL, mood, and sexual function. At follow-up visits women were asked to bring medications; remaining pills were counted and gel tubes weighed to provide medication adherence estimates.

### Outcomes/measurements

Menopause QOL was specified a priori as a secondary outcome, measured as change from baseline to 12 weeks in the total Menopause-Specific Quality of Life (MENQOL) questionnaire.<sup>22</sup> The MENQOL is a 29-item self-report measure of QOL designed to capture information on the presence and bother of symptoms, feelings, and experiences in the four domains of vasomotor, physical, psychosocial, and sexual functioning among midlife women in the menopause transition, total score range from 1 to 8. For each item, women were asked to report if they had experienced that symptom or feeling in the past 4 weeks, and if they had, to rate bother on a scale of 0 to 6 corresponding to “not bothered at all” to “extremely bothered.” These two items were combined to create a score from 1 (not experiencing symptoms or feeling) to 8 (extremely bothered). Each domain score was the average of the item scores in that domain (higher scores indicated poorer QOL). Validity, reliability, and responsiveness to change have been shown to be adequate to excellent.<sup>22</sup> In addition, we evaluated mood using the eight-item version of the depression module of the Patient Health Questionnaire (PHQ-8), which asks responders to indicate how often they have been bothered by a variety of symptoms and feelings in the last 2 weeks. The PHQ-8 depression scale is scored continuously with a range from 0 to 24; accepted categories of depression severity are 0 to 4 normal, 5 to 9 mild, and 10 or higher moderate to severe.<sup>23,24</sup> Anxiety was evaluated using the seven-item Generalized Anxiety Disorder (GAD-7) questionnaire, which also asks responders to indicate how often they have been bothered by specific symptoms or feelings in the previous 2 weeks. The GAD-7 score ranges from 0 to 21, with anxiety severity categorized as 0 to 4 normal, 5 to 9 mild, or 10 or more moderate to severe.<sup>25</sup>

## Other measurements

As previously reported, the primary outcome of the trial was severity of the most bothersome symptom defined by the participant at trial enrollment as vulvovaginal itching, pain, dryness, irritation, or pain with penetration. Severity was rated 0 to 3, signifying none, mild, moderate, or severe. At each visit, women completed a questionnaire about presence and severity of vulvovaginal symptoms. Demographic factors, smoking status, alcohol intake, and health status were assessed by questionnaire at baseline. Additional prespecified secondary outcomes included sexual functioning assessed using the Female Sexual Function Index (FSFI)<sup>26</sup> and the Female Sexual Distress Scale-Revised.<sup>27</sup>

## Statistical analysis

A modified intent-to-treat analysis included all randomized participants who provided follow-up QOL, depressive symptoms, or anxiety symptoms data at week 4, week 12, or both, regardless of treatment adherence.

Linear regression models were fit to summarize total MENQOL score, the four MENQOL domain scores, the PHQ-8 score, and the GAD-7 score at both 4 and 12 weeks as a function of treatment assignment, baseline value of the outcome measure, visit, and clinical site. Robust standard errors were calculated using generalized estimating equations to adjust for correlation between repeated outcome measures. We hypothesized that the effect of treatment on MENQOL score might be modified by baseline characteristics, specifically those related to sexual function. We assessed the interaction between treatment assignment and each baseline characteristic (reporting pain with sex as the most bothersome symptom and baseline FSFI [ $<$ median;  $\geq$ median]) within the repeated measures regression models. A sensitivity analysis evaluated intervention effects in models including only women who were adherent to treatment, defined as 80% or more medication use.

The planned sample size of the trial was determined by the primary trial endpoints. Reported *P* values were based on the Wald statistic, with two-sided *P* value of less than 0.05. Analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC).

## RESULTS

Three hundred two women were randomized to receive vaginal estradiol tablet plus placebo gel ( $n=102$ ), placebo tablet plus vaginal moisturizer ( $n=100$ ), or dual placebo ( $n=100$ ) (Fig. 1). Data on one or more domains of the MENQOL were available on 301 women ( $>99\%$ ) at baseline and 298 (99%) at 4 and/or 12 weeks of follow-up. Similarly for the PHQ-8 and GAD-7, data were available on 301 ( $>99\%$ ) women at baseline and 297 (97%) at follow-up.

Baseline characteristics were comparable between groups (Table 1). The mean age of study participants was 61 years; 88% were white and 85% were married or partnered. The most commonly reported most bothersome symptom was pain with vaginal penetration (182 [60%]). The majority of women

(81%) were sexually active: 67% with a male partner, 1% with a female partner, and 44% self-stimulation. Mean (SD) total MENQOL score overall was 3.3 (SD 3.1); 70 women (23.3%) had PHQ-8 scores indicating mild depressive symptoms and 18 (6.0%) had scores indicating moderate-severe depressive symptoms; 70 (23.3%) had GAD-7 scores indicating mild anxiety; and 28 (9.3%) had scores indicating moderate anxiety.

At completion of the trial, among women with both baseline and follow-up MENQOL data, 83 of 100 (83%) women randomized to estradiol tablets returned their tablets for counting and were more than 80% adherent, compared to 80 of 99 (80%) women randomized to placebo tablets. Seventy-four of 99 (74%) women randomized to vaginal moisturizer returned their gel for weighing and were more than 80% adherent, compared to 79 of 99 (79%) of women randomized to placebo gel.

## Effect of treatment assignment on total MENQOL scale and domain subscales

Total MENQOL scores declined, that is, menopause-related QOL improved, in all treatment groups (Table 2). Treatment with vaginal estradiol plus placebo gel resulted in significantly greater improvement in MENQOL scores compared to dual placebo (mean difference between groups at 12 weeks of  $-0.3$  (95% confidence interval [CI]  $-0.5, 0.0$ ;  $P=0.01$ ) (Table 2). A statistically significant treatment group difference favoring the vaginal estradiol group was also observed for the sexual function domain (Table 2) (mean difference at 12 weeks of  $-0.4$  (95% CI  $-1.0, 0.1$ ;  $P=0.005$ ) but not for any of the other domains (Table 2). Treatment with vaginal moisturizer plus placebo tablet did not result in greater improvement compared to dual placebo in total MENQOL scores (mean difference between groups at 12 weeks of  $0.2$ ; 95% CI  $-0.1, 0.4$ ;  $P=0.38$ ) or in any of the four domains of the MENQOL (Table 2).

Results were similar among adherent women (results not shown). We found no evidence of interactions between treatment assignment and selected characteristics (ie, presence or absence of sexual function-related most bothersome symptom and baseline FSFI) on total MENQOL score or sexual function domain score (data not shown).

## Effect of treatment assignment on depressive symptoms and anxiety

The mean PHQ-8 score at baseline was 3.5 (SD 3.8). PHQ-8 scores improved in all treatment groups at week 12 but there were no statistically significant differences between vaginal estrogen and placebo gel versus dual placebo or between vaginal moisturizer and placebo tablet versus dual placebo (Table 3). Similarly, there were no statistically significant differences between either active arm compared with dual placebo in GAD-7 change from baseline scores at week 12.

Results were similar among adherent women (data not shown).




FIG. 1. CONSORT diagram: randomization and follow-up of participants. MENQOL, Menopause Quality of Life.

## DISCUSSION

In this double-blind placebo controlled randomized trial studying postmenopausal women with moderate–severe vulvovaginal symptoms, women in all three treatment groups had small improvements in total menopause-related QOL over 12 weeks. Treatment with low-dose vaginal estradiol plus placebo gel improved total QOL and the sexual function domain of the MENQOL more than dual placebo. Treatment with a vaginal moisturizer and placebo tablet did not improve overall menopause-specific QOL or any of its domains more than dual placebo. Compared with placebo, neither vaginal estrogen nor vaginal moisturizer had greater effects on depressive symptoms or anxiety symptoms.

Previous trials of vaginal treatments for postmenopausal vulvovaginal complaints have focused on vaginal symptoms and sexual function as outcomes; few report a measure of QOL. Similar to the present study, randomized trials of the novel intravaginal agent, prasterone, and of an oral agent (bazedoxifene/conjugated estrogen), in women with vulvovaginal symptoms, observed greater improvement in total

MENQOL and sexual function domain scores relative to placebo. Treatment with bazedoxifene/conjugated estrogen resulted in a difference in the mean improvement in total MENQOL scores compared to placebo of  $-0.4$  to  $-0.5$ , depending on the dose of the estrogen ( $0.45$  or  $0.625$  mg); improvement in the sexual function domain was approximately  $0.6$  to  $0.7$  points greater with active treatment compared to placebo.<sup>28</sup> Similarly, treatment with intravaginal prasterone resulted in a mean difference in improvement in total MENQOL compared to placebo ranging from  $-0.2$  to  $-0.55$ , depending on the dose of prasterone; the sexual function domain improved  $0.6$  to  $1.2$ <sup>29</sup> over placebo. Weisberg et al<sup>30</sup> compared the vaginal estradiol-containing ring (Estring) to a  $25$   $\mu$ g vaginal estradiol tablet in an open-label, non–placebo-controlled study of women with vulvovaginal symptoms and did not observe effects on QOL as measured by the Medical Outcomes Study Questionnaire Short Form (SF-36) or its subscales. A nonrandomized study of very low concentration estriol gel ( $0.005\%$ ), which also used the SF-36 index found improved QOL in women using estrogen over 12

**TABLE 1.** Baseline characteristics among participants with baseline Menopause-Specific Quality of Life data

Baseline characteristic	Vaginal estradiol (n = 101)	Vaginal moisturizer (n = 100)	Dual placebo (n = 100)
Age at screening, y, mean (SD)	61 (4)	61 (4)	61 (4)
Age group, n (%)			
<55	3 (3)	0 (0)	1 (1)
55-59	35 (35)	42 (42)	47 (47)
60-64	42 (42)	41 (41)	28 (28)
≥65	21 (21)	17 (17)	24 (24)
Race/ethnicity, n (%)			
White	87 (86)	90 (90)	90 (90)
African American	7 (7)	3 (3)	2 (2)
Other/unknown	7 (7)	7 (7)	8 (8)
Body mass index, kg/m <sup>2</sup> , mean (SD)	27 (5)	26 (4)	26 (6)
Body mass index, kg/m <sup>2</sup> , n (%)			
<25	39 (39)	44 (44)	51 (51)
25-<30	37 (37)	42 (42)	26 (26)
≥30	21 (21)	14 (14)	21 (21)
Education, n (%)			
≤High school diploma	2 (2)	3 (3)	6 (6)
School after high school	31 (31)	27 (27)	31 (31)
College graduate	67 (66)	70 (70)	63 (63)
Marital status, n (%)			
Never married	8 (8)	2 (2)	4 (4)
Divorced	9 (9)	8 (8)	12 (12)
Widowed	1 (1)	0 (0)	0 (0)
Married or like relationship	83 (82)	90 (90)	84 (84)
Smoking, n (%)			
Never	66 (65)	67 (67)	66 (66)
Past	31 (31)	33 (33)	32 (32)
Current	4 (4)	0 (0)	2 (2)
Alcohol use (drinks/week), n (%)			
0	30 (30)	31 (31)	28 (28)
1 to <7	50 (50)	46 (46)	53 (53)
≥7	21 (21)	23 (23)	19 (19)
Sexually active, n (%)			
Yes	81 (80)	80 (80)	84 (84)
No	20 (20)	20 (20)	16 (16)
MENQOL measure, mean (SD)			
Total	3.3 (1.2)	3.2 (1.1)	3.3 (1.0)
Physical	3.0 (1.4)	2.9 (1.0)	3.0 (1.1)
Psychosocial	2.7 (1.4)	2.4 (1.1)	2.5 (1.2)
Sexual function	4.9 (2.0)	4.9 (2.2)	5.0 (2.0)
Vasomotor	2.7 (2.0)	2.6 (1.9)	2.6 (1.7)
Depression (PHQ-8), n (%)			
None (0-4)	69 (68)	75 (75)	69 (69)
Mild (5-9)	25 (25)	22 (22)	23 (23)
Moderate/severe (≥10)	7 (7)	3 (3)	8 (8)
Anxiety (GAD-7), n (%)			
None (0-4)	64 (63)	75 (75)	64 (64)
Mild (5-9)	25 (25)	21 (21)	24 (24)
Moderate/severe (≥10)	12 (12)	4 (4)	12 (12)
Sexual function (FSFI), mean (SD)	15.2 (5.9)	15.2 (6.5)	16.1 (6.6)
Sexual distress (FSDS-R), n (%)			
Never/rarely	15 (15)	12 (12)	18 (18)
Occasionally	33 (33)	33 (33)	33 (33)
Frequently/always	53 (53)	54 (54)	49 (49)
Most bothersome symptom, n (%)			
Vulvar and/or vaginal itching	10 (10)	4 (4)	6 (6)
Vulvar and/or vaginal soreness	5 (5)	7 (7)	2 (2)
Vulvar and/or vaginal irritation	7 (7)	4 (4)	8 (8)
Vaginal dryness	22 (22)	17 (17)	23 (23)
Pain with vaginal penetration	54 (54)	68 (68)	60 (60)
Self-reported health, n (%)			
Excellent	26 (26)	27 (27)	20 (20)
Very good	41 (41)	55 (55)	47 (47)
Good	33 (33)	15 (15)	30 (30)
Fair/poor	1 (1)	3 (3)	3 (3)

No significant differences observed between intervention and placebo groups.

FSDS-R, Female Sexual Distress Scale-Revised; FSFI, Female Sexual Function Index (range 0-27; 27 = best); GAD-7, Generalized Anxiety Disorder 7 (range 0-21; 0 = best); MENQOL, Menopause-Specific Quality of Life questionnaire (scale 1-8; 1 = best); PHQ-8, Patient Health Questionnaire 8 (range 0-24; 0 = best); SD, standard deviation.

TABLE 2. Menopause-Specific Quality of Life outcomes, change from baseline to weeks 4 and 12

MENQOL measures	Vaginal estradiol + placebo gel		Vaginal moisturizer + placebo tablet		Dual placebo		Vaginal estradiol + Pbo vs dual placebo		Vaginal moisturizer + Pbo vs dual placebo	
	N	Mean (95% CI)	N	Mean (95% CI)	N	Mean (95% CI)	Mean difference (95% CI)	P <sup>a</sup>	Mean difference (95% CI)	P <sup>a</sup>
Total								0.01		0.38
Baseline	99	3.3 (3.1, 3.6)	97	3.2 (3.0, 3.4)	95	3.3 (3.1, 3.5)	0.0 (-0.3, 0.3)		-0.1 (-0.4, 0.2)	
Week 4—baseline	91	-0.8 (-1.0, -0.6)	89	-0.5 (-0.6, -0.3)	85	-0.5 (-0.7, -0.4)	-0.3 (-0.5, 0.0)		0.1 (-0.2, 0.3)	
Week 12—baseline	89	-1.0 (-1.2, -0.8)	94	-0.5 (-0.7, -0.4)	86	-0.7 (-0.9, -0.6)	-0.3 (-0.5, 0.0)		0.2 (-0.1, 0.4)	
Physical								0.49		0.33
Baseline	101	3.0 (2.7, 3.3)	100	2.9 (2.7, 3.1)	100	3.0 (2.8, 3.2)	0.0 (-0.4, 0.3)		-0.2 (-0.4, 0.1)	
Week 4—baseline	97	-0.5 (-0.7, -0.3)	95	-0.2 (-0.3, 0.0)	95	-0.3 (-0.5, -0.1)	-0.2 (-0.4, 0.1)		0.1 (-0.1, 0.4)	
Week 12—baseline	96	-0.5 (-0.7, -0.2)	97	-0.3 (-0.5, -0.1)	95	-0.5 (-0.7, -0.3)	0.0 (-0.3, 0.3)		0.2 (-0.1, 0.4)	
Psychosocial								0.59		0.69
Baseline	101	2.7 (2.4, 3.0)	98	2.4 (2.2, 2.6)	99	2.5 (2.3, 2.8)	0.2 (-0.2, 0.5)		-0.1 (-0.4, 0.2)	
Week 4—baseline	97	-0.2 (-0.4, 0.1)	94	-0.1 (-0.3, 0.1)	96	-0.1 (-0.3, 0.1)	-0.1 (-0.4, 0.2)		0.0 (-0.3, 0.3)	
Week 12—baseline	97	-0.4 (-0.7, -0.2)	96	-0.2 (-0.4, 0.0)	93	-0.2 (-0.4, 0.0)	-0.2 (-0.6, 0.1)		0.0 (-0.3, 0.3)	
Sexual function								0.005		0.13
Baseline	99	4.9 (4.5, 5.3)	99	4.9 (4.5, 5.4)	97	5.0 (4.6, 5.4)	-0.1 (-0.6, 0.5)		0.0 (-0.6, 0.6)	
Week 4—baseline	94	-2.2 (-2.6, -1.8)	94	-1.5 (-1.9, -1.1)	91	-1.6 (-2.0, -1.2)	-0.7 (-1.2, -0.1)		0.1 (-0.4, 0.7)	
Week 12—baseline	92	-2.3 (-2.7, -1.8)	98	-1.3 (-1.7, -0.9)	90	-1.8 (-2.2, -1.4)	-0.4 (-1.0, 0.1)		0.5 (0.0, 1.1)	
Vasomotor								0.08		0.56
Baseline	101	2.7 (2.3, 3.1)	100	2.6 (2.3, 3.0)	99	2.6 (2.3, 3.0)	0.1 (-0.4, 0.6)		0.0 (-0.5, 0.5)	
Week 4—baseline	99	-0.3 (-0.5, -0.1)	96	-0.2 (-0.5, 0.0)	97	-0.2 (-0.5, 0.1)	-0.1 (-0.4, 0.2)		0.0 (-0.4, 0.3)	
Week 12—baseline	98	-0.7 (-1.0, -0.5)	98	-0.4 (-0.6, -0.2)	95	-0.3 (-0.5, -0.1)	-0.4 (-0.7, -0.1)		-0.1 (-0.4, 0.2)	

CI, confidence interval; MENQOL, menopause-specific quality of life (range 1-8; 1 = best); Pbo, placebo.

<sup>a</sup>P values from contrasts comparing each treatment versus placebo in a repeated measures linear model of outcome as a function of randomization assignment, baseline value of the outcome measure, visit week (4 or 12), and clinical site.

weeks, primarily due to improvements in physical domains as opposed to mental domains.<sup>31</sup> A case series of a novel intravaginal estriol/progesterone suppository reported improvement from baseline in MENQOL during 6 months, largely due to improvements in the sexual function domain, but this investigation is limited by the absence of a comparable control group.<sup>32</sup>

Although small, the magnitude of the effect of vaginal estradiol on total MENQOL in our study (-0.3 [95% CI -0.5, 0.0]) is similar to that observed for low-dose oral 17-beta estradiol 0.5 mg/day (-0.4 [95% CI -0.7, -0.2]) in a previous trial conducted in postmenopausal women with bothersome hot flashes.<sup>33</sup> In that trial, the improvement in total MENQOL was associated with changes in three of the four domains, with the exception of psychosocial.

Of note, neither low-dose vaginal estradiol nor vaginal moisturizer had a greater impact than placebo on most bothersome vulvovaginal symptom severity or sexual functioning as measured by the FSFI in the primary trial

analyses.<sup>21</sup> However, in this secondary analysis of trial data, we did observe a significantly larger improvement in the sexual function domain of the MENQOL among women assigned to vaginal estradiol and placebo gel. The three questions on the MENQOL regarding sexual functioning ask how much the responder has been bothered by a decrease in sexual desire, vaginal dryness during intercourse, and avoiding intimacy; thus, improvements reflect feeling less bothered on these dimensions. In contrast, the FSFI's 19 questions are more detailed and many ask responders to describe how often they felt sexual desire or interest, felt sexually aroused, were satisfied with their arousal during sexual activity, became lubricated during sexual activity, and experienced pain with vaginal penetration. These questions, which focus on frequency of sexual feelings, activity, and satisfaction, capture different aspects of sexual function than the MENQOL. The lack of alignment of the null treatment effects on the FSFI with modest treatment effects of vaginal estradiol on total and sexual MENQOL scores

TABLE 3. Mood outcomes, change from baseline to week 12

Measure	Vaginal estradiol + placebo gel		Vaginal moisturizer + placebo tablet		Dual placebo		Vaginal estradiol + Pbo vs dual placebo		Vaginal moisturizer + Pbo vs dual placebo	
	N	Mean (95% CI)	N	Mean (95% CI)	N	Mean (95% CI)	Mean difference (95% CI)	P <sup>a</sup>	Mean difference (95% CI)	P <sup>a</sup>
Depression (PHQ-8)								0.63		0.83
Baseline	101	3.5 (2.8, 4.2)	100	3.2 (2.6, 3.7)	100	3.8 (3.1, 4.5)	-0.3 (-1.3, 0.7)		-0.6 (-1.5, 0.3)	
Week 12—baseline	97	-0.5 (-1.2, 0.1)	99	-0.2 (-0.8, 0.4)	96	-0.5 (-1.0, 0.0)	-0.1 (-0.9, 0.7)		0.3 (-0.5, 1.0)	
Anxiety (GAD-7)								0.17		0.99
Baseline	101	4.1 (3.2, 5.0)	100	2.9 (2.3, 3.6)	100	4.1 (3.2, 4.9)	0.0 (-1.2, 1.2)		-1.2 (-2.2, -0.1)	
Week 12—baseline	98	-1.2 (-1.8, -0.5)	99	0.0 (-0.6, 0.7)	96	-0.6 (-1.4, 0.2)	-0.6 (-1.6, 0.4)		0.6 (-0.4, 1.6)	

CI, confidence interval; GAD-7, Generalized Anxiety Disorder 7 (range 0-21; 0 = best); Pbo, placebo; PHQ-8, Patient Health Questionnaire 8 (range 0-24, 0 = best).

<sup>a</sup>P values from contrasts comparing each treatment versus placebo in a linear model of week 12 outcome as a function of randomization assignment, baseline value of the outcome measure, and clinical site.

suggests that different information about sexual QOL is detected when women are asked to provide a personal assessment of how much they are bothered by changes in sexual desire, vaginal dryness during intercourse, and avoiding intimacy. The implication is that multiple approaches to measuring sexual QOL are needed when assessing interventions to improve vaginal dryness or dyspareunia.

We did not observe effects of vaginal estradiol or vaginal moisturizer, as compared to placebo, on anxiety or depressive symptoms. The causal paths affecting anxiety and depression symptoms are complex and variable. Therapies directed at vaginal symptoms are most likely to improve symptoms such as dyspareunia or dryness, which in turn may improve sexual function. Twelve weeks of treatment with modest improvements in overall and sexual QOL may not be sufficient to reverse longer-term effects of sexual problems on mood or anxiety. Alternatively, the psychosocial underpinnings of depression and anxiety symptoms may not be related to sexual problems in many women, or the mood symptoms may be contributing to sexual problems (reverse causation). In addition, very few women in our trial had moderate or severe levels of depression or anxiety, making it difficult to measure improvements in these parameters.

Strengths of this trial include the use of reliable and valid measures of menopause-related QOL and mood symptoms, use of placebos for both the vaginal estradiol and the vaginal moisturizer, and excellent participant retention and medication adherence. The study was not designed to compare the vaginal estradiol to vaginal moisturizer interventions directly.

## CONCLUSIONS

Our results suggest that treatment with vaginal estradiol tablets in women with bothersome vulvovaginal symptoms improves overall menopause-related QOL more than placebo treatment. We did not observe a similar effect for a vaginal moisturizer. These results suggest that there may be modest benefit of treatment with vaginal estradiol tablets for improving aspects of sexual function captured in the MENQOL. Other considerations such as cost, ease of obtaining treatment, and personal preferences regarding vaginal treatment options may influence individual therapeutic choices.

## REFERENCES

- DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. *J Womens Health (Larchmt)* 2015;24:713-722.
- Minkin MJ, Reiter S, Maamari R. Prevalence of postmenopausal symptoms in North America and Europe. *Menopause* 2015;22:1231-1238.
- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. *J Sex Med* 2009;6:2133-2142.
- Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey. *J Sex Med* 2013;10:1790-1799.
- Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. *Maturitas* 2010;67:233-238.
- Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: country-specific comparisons of postmenopausal women's perceptions, experiences and needs. *Maturitas* 2016;91:81-90.
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause* 2013;20:888-902.
- Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause: summary of NICE guidance. *BMJ* 2015;351:h5746.
- Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause* 2016;23:243-256.
- Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. *Menopause* 2013;20:623-630.
- Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol* 1998;92 (4 pt 2):722-727.
- Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2006; CD001500.
- Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. *Obstet Gynecol* 2008;111:67-76.
- Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. *Eur J Obstet Gynecol Reprod Biol* 1992;44:137-144.
- Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. *Obstet Gynecol* 2008;112:1053-1060.
- Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic BD, Sprem M. Local estrogen treatments in patients with urogenital symptoms. *Int J Gynaecol Obstet* 2003;82:187-197.
- Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. *Menopause* 2010;17:480-486.
- Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. *Gynecol Endocrinol* 2010;26:404-412.
- Bygdeman M, Swahn ML. Replens versus dienestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. *Maturitas* 1996;23:259-263.
- Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. *J Clin Oncol* 1997;15:969-973.
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. *JAMA Intern Med* 2018;178:681-690.
- Hilditch JR, Lewis J, Peter A, et al. A Menopause-Specific Quality of Life Questionnaire: development and psychometric properties. *Maturitas* 1996;24:161-175.
- Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med* 2007;22:1596-1602.
- Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 2009;114:163-173.
- Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing Generalized Anxiety Disorder: the GAD-7. *Arch Intern Med* 2006;166:1092-1097.
- Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000;26:191-208.
- Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. *J Sex Med* 2008;5:357-364.

28. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. *Climacteric* 2010;13:132-140.
29. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. *Menopause* 2009;16:923-931.
30. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. *Climacteric* 2005;8:83-92.
31. Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. *Menopause* 2016;23:47-54.
32. Chollet JA, Carter G, Meyn LA, Mermelstein F, Balk JL. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. *Menopause* 2009;16:978-983.
33. Caan B, LaCroix AZ, Joffe H, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. *Menopause* 2015;22:607-615.